160 related articles for article (PubMed ID: 16278477)
1. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.
Ryan CJ; Small EJ
J Clin Oncol; 2005 Nov; 23(32):8225-31. PubMed ID: 16278477
[TBL] [Abstract][Full Text] [Related]
2. High risk biochemical relapse and the timing of androgen deprivation therapy.
Ryan CJ; Small EJ
J Urol; 2006 Dec; 176(6 Pt 2):S61-5. PubMed ID: 17084171
[TBL] [Abstract][Full Text] [Related]
3. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
4. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; MartÃnez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
[TBL] [Abstract][Full Text] [Related]
6. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
8. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in hormonal therapy for advanced prostate cancer.
Daskivich TJ; Oh WK
Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
[TBL] [Abstract][Full Text] [Related]
10. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy in locally advanced and metastatic prostate cancer.
Ryan CJ; Small EJ
Minerva Urol Nefrol; 2006 Sep; 58(3):119-26. PubMed ID: 17124482
[TBL] [Abstract][Full Text] [Related]
12. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
13. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
[TBL] [Abstract][Full Text] [Related]
14. Advanced prostatic carcinoma. Early versus late endocrine therapy.
Kozlowski JM; Ellis WJ; Grayhack JT
Urol Clin North Am; 1991 Feb; 18(1):15-24. PubMed ID: 1992569
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
16. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
17. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
Roach M
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
[TBL] [Abstract][Full Text] [Related]
18. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
19. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
20. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
Armstrong AJ; Febbo PG
Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]